Research
Leerink Partners Downgrades Regeneron Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $641 From $792
Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $852.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$REGN